Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine

Written by Takashima S, Oka Y, Fujiki F

Recently, cancer immunotherapies are becoming a standard therapeutic option. To improve their efficacy, identification of biomarkers is important to select responsive patients. In this study, we identified SDC-4 as a biomarker to predict clinical outcome using peripheral blood mononuclear cells obtained from patients with glioblastoma, a malignant brain tumor, who were treated with WT1 peptide vaccine. With 30 samples of peripheral blood mononuclear cells prior to vaccination, 32 candidate genes were filtrated by microarray, and finally only SDC-4 was validated by RT-PCR using another 23 samples. Accordingly, 1-year survival rates were 64.0 and 18.5% in SDC4-low and -high patients, respectively....

To view this content, please register now for access

It's completely free